清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

The Novel Proteasome Inhibitor 5-Amino-8-Hydroxyquinole (5AHQ) Overcomes Bortezomib Resistance in Malignant Hematological Cell Line Models Harboring Mutations in the PSMB5 Gene.

硼替佐米 蛋白酶体 蛋白酶体抑制剂 细胞培养 癌症研究 生物 药理学 多发性骨髓瘤 医学 化学 分子生物学 免疫学 生物化学 遗传学
作者
N. Franke,Johan van Meerloo,Linda M. Slot,Xiaoming Li,Tabitha E. Wood,Katarina Vojtekova,Sue Ellen Verbrugge,Gertjan J.L. Kaspers,Robert A. Batey,Aaron D. Schimmer,Gerrit Jansen,Jacqueline Cloos
出处
期刊:Blood [Elsevier BV]
卷期号:114 (22): 940-940 被引量:1
标识
DOI:10.1182/blood.v114.22.940.940
摘要

Abstract Abstract 940 The proteasome inhibitor Bortezomib (BTZ, Velcade®) specifically inhibits the catalytic beta 5 subunit of the proteasome, thereby interfering in the degradation of proteins involved in cell-cycling, NF-kB activation, apoptosis induction and micro-environmental interactions. The introduction of BTZ has shown promising results in the treatment of Multiple Myeloma (MM), Non-Hodgkin lymphoma and leukemia. Despite these encouraging results, clinical trials in MM also revealed that a significant proportion of patients acquired resistance to BTZ mono-therapy. Previously we reported the development of three different BTZ-resistant cell line models, including the AML THP-1 cell-line (Oerlemans & Franke et al, Blood 2008), the T-ALL CCRF-CEM-C7 cell-line and the MM RPMI-8226 cell line (Franke et al, ASH 2008) after chronic exposure to stepwise increasing concentrations of BTZ. The aim of our current study was to further elucidate the molecular basis of BTZ resistance in these cell lines and investigate whether the resistant phenotype could be overcome by the second generation proteasome inhibitor 5-amino-8-hydroxyquinole (5AHQ), acting as a non-competitive inhibitor of the non-catalytic alpha-7 subunit of the proteasome (Li et al. ASH 2008). When added to intact cells, cell extracts, or isolated rabbit reticulocyte proteasomes (gift of A Navon, Weizmann Institute of Science, Israel), 5AHQ inhibited the chymotrypsin-like enzymatic activity of the proteasome with IC50's of 6.9 ± 0.05 uM, 4.2 ± 0.6 uM, and 2.1 ± 0.18 μM, respectively. Cells were initially selected for growth at 7 nM BTZ to acquire low levels of BTZ resistance (2-3 fold higher IC50 concentrations) and subsequently challenged to higher concentrations of BTZ (up to 500 nM) to provoke higher resistance levels. Sequencing of the PSMB5 gene, encoding for the beta 5 proteasome subunit, revealed a series of mutations in individual BTZ-resistant subclones. An overview of the mutation site in the PSMB5 gene, the amino acid position at which substitutions take place at the beta 5 subunit protein level, and the functional implication of each mutation are depicted in the table below. Subsequently, we determined whether THP-1, CEM and 8226 cells with low and high levels of BTZ resistance would be sensitive towards the new proteasome inhibitor 5AHQ. Strikingly, all BTZ-resistant selectants retained full sensitivity towards 5AHQ (IC50: 4-7 μM, measured in a 4-day MTT cytotoxicity assay) as compared to parental cells. Together, these data indicate that in vitro selection of low and high levels of BTZ resistance in 3 hematological cell lines is accompanied by the introduction of multiple mutations of amino acids, all of which have key positions in BTZ binding within the active site of the proteasome beta 5 subunit. Notably, Ala49 mutations were independently observed in all 3 cell lines selected for BTZ concentrations > 100 nM. Knowledge of specific mutations in the PSMB5 gene that can confer BTZ resistance allows purposive screening for these types of mutations in clinical samples of BTZ refractory patients. In this respect, the notion that 5AHQ can bypass BTZ resistance related to single or multiple mutations in the PSMB5 gene, supports further preclinical development and clinical application of this drug. This study is supported by VUmc - Stichting Translational Research (STR) and The Netherlands Organization for Health Research and Development (ZonMw), The Leukemia and Lymphoma Society and the Ontario Institute for Cancer Research through funding from the Ministry of Research and Innovation, Province of Ontario. Disclosures: No relevant conflicts of interest to declare.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
优秀的尔风完成签到,获得积分10
4秒前
Emperor完成签到 ,获得积分0
14秒前
wangsai0532完成签到,获得积分10
20秒前
科研通AI2S应助科研通管家采纳,获得30
23秒前
CJY完成签到 ,获得积分10
27秒前
姚芭蕉完成签到 ,获得积分0
30秒前
39秒前
54秒前
蝎子莱莱xth完成签到,获得积分10
1分钟前
氢锂钠钾铷铯钫完成签到,获得积分10
1分钟前
Square完成签到,获得积分10
1分钟前
1分钟前
叁月二完成签到 ,获得积分10
1分钟前
1分钟前
2分钟前
wjx完成签到 ,获得积分10
2分钟前
俏皮元珊完成签到 ,获得积分10
2分钟前
2分钟前
大个应助科研通管家采纳,获得20
2分钟前
搜集达人应助科研通管家采纳,获得30
2分钟前
elisa828发布了新的文献求助10
2分钟前
zijingsy完成签到 ,获得积分10
2分钟前
Owen应助像风一样采纳,获得10
2分钟前
单小芫完成签到 ,获得积分10
2分钟前
2分钟前
像风一样完成签到,获得积分20
2分钟前
像风一样发布了新的文献求助10
2分钟前
2分钟前
深情安青应助念臻采纳,获得10
2分钟前
六六吃了梅完成签到,获得积分20
3分钟前
Jally完成签到 ,获得积分10
3分钟前
王洋完成签到,获得积分10
3分钟前
myq完成签到 ,获得积分10
3分钟前
念臻完成签到,获得积分10
3分钟前
3分钟前
枫威完成签到 ,获得积分10
3分钟前
念臻发布了新的文献求助10
3分钟前
lod完成签到,获得积分10
3分钟前
香锅不要辣完成签到 ,获得积分10
3分钟前
3分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968521
求助须知:如何正确求助?哪些是违规求助? 3513341
关于积分的说明 11167298
捐赠科研通 3248700
什么是DOI,文献DOI怎么找? 1794434
邀请新用户注册赠送积分活动 875030
科研通“疑难数据库(出版商)”最低求助积分说明 804664